Centralized procurement has led to a sharp drop in the price of generic drugs, which poses a direct challenge to the company's revenue. However, key generic drug companies such as Beite Pharmaceuticals have maintained steady revenue growth under the background of centralized procurement with their strong R&D strength and market competitiveness.

Data show that its sales of pharmaceutical preparations have continued to grow, with a compound growth rate of up to 30.7%, especially in 2021, which has achieved a leapfrog growth.

Remarkable performance and steady growth

In recent years, Chengdu Beite Pharmaceuticals' performance has continued to grow, showing strong development resilience and potential. In 2023, the company's sales of pharmaceutical preparations reached 7.41 billion yuan. From 2016 to 2023, the compound growth rate of sales of preparations was as high as 30.7%, especially in 2021, Beite Pharmaceuticals' performance achieved a leapfrog growth, a year-on-year increase of 98.0% compared with 2020.
The key to Beite Pharmaceuticals' excellent results lies in its multi-faceted scientific planning and active layout.

The company has a deep insight into industry trends and market demand, laying a solid foundation for future development. In terms of R&D investment, Beite Pharmaceuticals has continued to increase its financial and human investment. In the disclosed information, the R&D investment in 2017-2021 accounted for more than 10% of its revenue, consolidating the market position of existing products and opening up new growth points for the company. In terms of market expansion, Beite Pharmaceuticals keeps pace with the times and actively deploys multiple online and offline channels. Through the integration of online and offline, it has built a broad and stable marketing network, effectively improving brand awareness and market share.

This series of scientific planning and active layout have jointly promoted the rapid development of Beite Pharmaceuticals and achieved remarkable results. Let's take a look at the specific situation of Beite Pharmaceuticals' product layout and market layout.

Rich products and complete pipelines

Beite Pharmaceuticals has built a rich and diverse product pipeline that covers a wide range of treatment areas and can provide patients with comprehensive treatment plans.

Beite Pharmaceuticals has strong R&D capabilities. In recent years, the number of drugs approved for listing has increased year by year, and 34 drugs will be listed in 2024. At present, more than 20 first-copy varieties have been successfully launched, such as furosemide oral solution, rilpivirine tablets, dacomitinib tablets, etc.

Beite Pharmaceuticals' listed products cover multiple therapeutic areas, with the largest layout in systemic anti-infective drugs, as well as multiple therapeutic areas such as blood and hematopoietic organs, digestive system and metabolism, cardiovascular and cerebrovascular system, respiratory system, and nervous system.
In the contrast agent sector, a number of contrast agent products have also been approved for marketing, including gadobenate dimeglumine injection, iodixanol injection, and iopamidol injection.

At the same time, Beite Pharmaceuticals is actively engaged in the research and development of innovative drugs. The layout of its R&D pipeline involves cutting-edge directions such as small nucleic acid drugs, antibody drugs, cell and gene therapy drugs, and nuclear drugs, covering multiple therapeutic areas such as tumors, respiratory, obstetrics and gynecology, cardiovascular and cerebrovascular, metabolism, and neurology. At present, many innovative drug projects are progressing steadily, and some projects have achieved key phased results. For example, the first siRNA drug for the treatment of transthyretin amyloidosis in China and the second in the world, BPR-30221616 injection, has been approved for clinical trials. These innovative drugs are expected to provide a strong impetus for the company's future performance growth.
Control the terminal, diversify the model.

Beite Pharmaceuticals innovatively adopts a mixed marketing model of "control the terminal, diversify the model", and has established two major marketing systems for preparations and raw materials. Its marketing network covers the whole country and extends to many countries and regions around the world.

In the in-hospital market, Beite Pharmaceuticals actively participates in the centralized procurement of drugs organized by the state. From the "4+7" pilot to the tenth batch of "national centralized procurement", the company has successfully selected 52 varieties. In the tenth batch of national centralized procurement of drugs, a total of 15 drugs under Beite Pharmaceuticals were selected, including amikacin sulfate injection, piperacillin sodium injection, digoxin injection, etc.

In addition, Beite Pharmaceuticals has also vigorously expanded its online sales channels, cooperated with professional e-commerce operation service teams such as Xiaorou Health, and carried out online e-commerce business across the country, promoting and selling dozens of advantageous varieties in multiple fields such as anti-infection, cardiovascular and cerebrovascular, digestion, metabolism, and pediatrics online. Through online channels, Beite Pharmaceuticals can reach a wider range of consumer groups, effectively enhance product awareness and sales, and further expand market share.

Standing at a new starting point for development, the future of Chengdu Beite Pharmaceuticals is full of infinite possibilities. With the continuous deepening of innovative drug research and development, Beite Pharmaceuticals is expected to make more breakthrough progress in the field of major disease treatment, launch more innovative drugs with independent intellectual property rights, and provide patients with more and more effective treatment options. With the strong strength accumulated in product research and development, market layout, team building and other aspects, Chengdu Beite Pharmaceuticals is expected to write a more brilliant chapter in the future.

https://news.yaozh.com/archive/45109.html